Sihai network

Will AIDS be defeated

AIDS is a difficult problem in the world. People have been talking about AIDS. A new study shows that cows have the 'unusual' ability to fight AIDS. The new research could help develop a vaccine for humans. What does it mean that HIV vaccines produce antibodies?

According to the independent website on July 22, scientists found that the powerful immune system of animals can quickly generate special antibodies, so that HIV can not play a destructive role.

Johnson & Johnson announced the results of the world's first human clinical trial of HIV vaccine on July 24. 393 healthy volunteers were recruited in this multicenter, randomized, placebo-controlled, double-blind phase-1 / 2A clinical trial. The results showed that the volunteers were well tolerated by HIV vaccine, and 100% of them produced anti HIV antibodies.

The volunteers of this experiment are from the United States, Rwanda, Uganda, South Africa and Thailand. The specific experiment is undertaken by Janssen Pharmaceutical Company of Johnson & Johnson company. The technology comes from Harvard University Medical School and other research units in the United States. Johnson & Johnson company provides financial support.

According to the introduction, the HIV vaccine is mosaic vaccine, that is to use a variety of HIV antigens (gene fragments) together to form a vaccine with strong stimulation on the body's immune system and can generate effective antibodies, known as the approach vaccine.

In addition to producing anti HIV antibodies in 100% of the subjects, the approach vaccine also reduced the risk of single exposure to HIV infection by 94%, and 66% of the subjects were still protected from HIV infection after six exposures.

In the vaccine trial, the strategy of "primary immunization - enhanced immunization" was adopted, that is, the subjects received 4 times of vaccine injection in total, the first two shots were primary immunization, and the last two shots were enhanced immunization. 48 weeks after the injection, the subjects had no side effects, and blood tests showed that all the people had antibodies against HIV. The risk of HIV infection was reduced by 94% in the assessment of the actual protection of the subjects.

It is reported that the remarkable effect of the mosaic vaccine is mainly due to the design of the vaccine according to the characteristics of HIV. The most important thing is to use a variety of HIV antigens, that is, to select genes from different HIV subtypes, which are generated by virus vectors to form a vaccine containing a variety of HIV antigens.